New scan could catch breast cancer spread that standard tests miss
NCT ID NCT07313033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of PET scan using a tracer called 68Ga-FAPI-46 to find cancer that has spread in patients with lobular breast cancer. Standard scans often miss these metastases. The trial will enroll 45 adults whose standard PET scan was negative or unclear, and see if the new scan can spot hidden lesions confirmed by biopsy. If it works, it could lead to better treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a more accurate way to detect breast cancer spread, helping patients avoid undertreatment.
What could go wrong
This is a very early, small study (45 people) with no results yet. The new scan may not find more lesions than the standard scan, and false positives are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lyon sud Hospital center - Hospices Civils de Lyon
Lyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••